Chemistry (Weinheim an der Bergstrasse, Germany). 2019 Sep 27. doi: 10.1002/chem.201903605 |
The first anticancer tris(pyrazolyl)borate molybdenum(IV) complexes: tested in vitro and in vivo - a comparison of O,O-, S,O-, and N,N-chelate effects. |
Berasaluce I1, Cseh K2, Roller A3, Hejl M4, Heffeter P5, Berger W6, Jakupec MA7, Kandioller W8, Malarek MS9, Keppler BK10 |
Abstract The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3-isopropylpyrazolyl)borate (TpiPr), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed include (O,O-) (S,O-) (N,N-) donors which have been successfully coordinated to the molybdenum center by means of oxygen-atom transfer (OAT) reactions from the known MoVI starting material, TpiPrMoO2Cl. The synthesized complexes were characterized by standard analytical methods, and where possible by X-ray diffraction analysis. The aqueous stability of the compounds was studied by means of UV/Vis spectroscopy and the impact of the attached ligand scaffolds on the oxidation potentials (MoIV to MoV) was studied by cyclic voltammetry. Utilizing polyvinylpyrrolidone (PVP) as a solubilizing agent, adequate aqueous solubility for biological tests was obtained. The anticancer activity and preliminary mode of action studies have been performed in vitro and in vivo. |
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
KEYWORDS: anticancer, biological tests, in vivo experiments, molybdenum, tris(pyrazolyl)borate |
Publikations ID: 31560142 Quelle: öffnen |